Targeting hedgehog signaling reduces self-renewal in embryonal rhabdomyosarcoma

Oncogene

Volumn 35, Issue 16, 2016, Pages 2020-2030

  Satheesha, S ^a   Manzella, G ^a   Bovay, A ^a   Casanova, E A ^a   Bode, P K ^a,b   Belle, R ^a   Feuchtgruber, S ^c   Jaaks, P ^a   Dogan, N ^a   Koscielniak, E ^c   Schafer B W ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^b UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^c OLGAHOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPAMINE; DOXORUBICIN; FIRTECAN; GANT 61; IRINOTECAN; MESSENGER RNA; MYOGENIN; SONIC HEDGEHOG PROTEIN; SONIDEGIB; TRANSCRIPTION FACTOR GLI1; TRANSCRIPTION FACTOR NANOG; UNCLASSIFIED DRUG; VISMODEGIB;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CANCER PROGNOSIS; CANCER RESISTANCE; CARCINOGENESIS; CELL DIFFERENTIATION; CELL MOTILITY; CHILDHOOD CANCER; CONTROLLED STUDY; DRUG TARGETING; EMBRYONAL RHABDOMYOSARCOMA; FEMALE; GAIN OF FUNCTION MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LOSS OF FUNCTION MUTATION; MALE; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHABDOMYOSARCOMA CELL LINE; SIGNAL TRANSDUCTION; STEM CELL SELF-RENEWAL; METABOLISM; PATHOLOGY; PROGNOSIS; TUMOR CELL CULTURE;

CARCINOGENESIS; HEDGEHOG PROTEINS; HUMANS; PROGNOSIS; RHABDOMYOSARCOMA, EMBRYONAL; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 84937597929     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2015.267     Document Type: Article

References (40)

1. Chen X, Stewart E, Shelat AA, Qu C, Bahrami A, Hatley M et al. Targeting oxidative stress in embryonal rhabdomyosarcoma. Cancer Cell 2013; 24: 710-724.
2. Hawkins DS, Gupta AA, Rudzinski ER. What is new in the biology and treatment of pediatric rhabdomyosarcoma? Curr Opin Pediatr 2014; 26: 50-56.
3. Shern JF, Chen L, Chmielecki J, Wei JS, Patidar R, Rosenberg M et al. Comprehensive genomic analysis of rhabdomyosarcoma reveals a landscape of alterations affecting a common genetic axis in fusion-positive and fusionnegative tumors. Cancer Discov 2014; 4: 216-231.
4. Zibat A, Missiaglia E, Rosenberger A, Pritchard-Jones K, Shipley J, Hahn H et al. Activation of the hedgehog pathway confers a poor prognosis in embryonal and fusion gene-negative alveolar rhabdomyosarcoma. Oncogene 2010; 29: 6323-6330.
5. Paulson V, Chandler G, Rakheja D, Galindo RL, Wilson K, Amatruda JF et al. High-resolution array CGH identifies common mechanisms that drive embryonal rhabdomyosarcoma pathogenesis. Genes Chromosomes Cancer 2011; 50: 397-408.
6. Pressey JG, Anderson JR, Crossman DK, Lynch JC, Barr FG. Hedgehog pathway activity in pediatric embryonal rhabdomyosarcoma and undifferentiated sarcoma: a report from the Children's Oncology Group. Pediatr Blood Cancer 2011; 57: 930-938.
7. Belyea B, Kephart JG, Blum J, Kirsch DG, Linardic CM. Embryonic signaling pathways and rhabdomyosarcoma: contributions to cancer development and opportunities for therapeutic targeting. Sarcoma 2012; 2012: 406239.
8. Hui CC, Angers S. Gli proteins in development and disease. Annu Rev Cell Dev Biol 2011; 27: 513-537.
9. Amakye D, Jagani Z, Dorsch M. Unraveling the therapeutic potential of the Hedgehog pathway in cancer. Nat Med 2013; 19: 1410-1422.
10. Langenau DM, Keefe MD, Storer NY, Guyon JR, Kutok JL, Le X et al. Effects of RAS on the genesis of embryonal rhabdomyosarcoma. Genes Dev 2007; 21: 1382-1395.
11. Walter D, Satheesha S, Albrecht P, Bornhauser BC, D'Alessandro V, Oesch SM et al. CD133 positive embryonal rhabdomyosarcoma stem-like cell population is enriched in rhabdospheres. PLoS One 2011; 6: e19506.
12. Ignatius MS, Chen E, Elpek NM, Fuller AZ, Tenente IM, Clagg R et al. In vivo imaging of tumor-propagating cells, regional tumor heterogeneity, and dynamic cell movements in embryonal rhabdomyosarcoma. Cancer Cell 2012; 21: 680-693.
13. Stecca B, Ruiz i Altaba A. A GLI1-p53 inhibitory loop controls neural stem cell and tumour cell numbers. EMBO J 2009; 28: 663-676.
14. Mao J, Ligon KL, Rakhlin EY, Thayer SP, Bronson RT, Rowitch D et al. A novel somatic mouse model to survey tumorigenic potential applied to the Hedgehog pathway. Cancer Res 2006; 66: 10171-10178.
15. Ehnman M, Missiaglia E, Folestad E, Selfe J, Strell C, Thway K et al. Distinct effects of ligand-induced PDGFRalpha and PDGFRbeta signaling in the human rhabdomyosarcoma tumor cell and stroma cell compartments. Cancer Res 2013; 73: 2139-2149.
16. Vidal SJ, Rodriguez-Bravo V, Galsky M, Cordon-Cardo C, Domingo-Domenech J. Targeting cancer stem cells to suppress acquired chemotherapy resistance. Oncogene 2014; 33: 4451-4463.
17. Voronova A, Coyne E, Al Madhoun A, Fair JV, Bosiljcic N, St-Louis C et al. Hedgehog signaling regulates MyoD expression and activity. J Biol Chem 2013; 288: 4389-4404.
18. Theunissen TW, Silva JC. Switching on pluripotency: a perspective on the biological requirement of Nanog. Philos Trans R Soc Lond B Biol Sci 2011; 366: 2222-2229.
19. Wang ML, Chiou SH, Wu CW. Targeting cancer stem cells: emerging role of Nanog transcription factor. Onco Targets Ther 2013; 6: 1207-1220.
20. Po A, Ferretti E, Miele E, De Smaele E, Paganelli A, Canettieri G et al. Hedgehog controls neural stem cells through p53-independent regulation of Nanog. EMBO J 2010; 29: 2646-2658.
21. Zbinden M, Duquet A, Lorente-Trigos A, Ngwabyt SN, Borges I, Ruiz i Altaba A. NANOG regulates glioma stem cells and is essential in vivo acting in a crossfunctional network with GLI1 and p53. EMBO J 2010; 29: 2659-2674.
22. Wachtel M, Runge T, Leuschner I, Stegmaier S, Koscielniak E, Treuner J et al. Subtype and prognostic classification of rhabdomyosarcoma by immunohistochemistry. J Clin Oncol 2006; 24: 816-822.
23. Merchant AA, Matsui W. Targeting Hedgehog-a cancer stem cell pathway. Clin Cancer Res 2010; 16: 3130-3140.
24. Vermeulen L, de Sousa e Melo F, Richel DJ, Medema JP. The developing cancer stem-cell model: clinical challenges and opportunities. Lancet Oncol 2012; 13: e83-e89.
25. Satheesha S, Schäfer BW. Cancer stem cells in pediatric sarcomas. In: Hayat MA (ed). Stem Cells and Cancer Stem Cells: Therapeutic Applications in Disease and Injury, vol. 11. Springer: Dordrecht 2014, pp 111-126.
26. Brack AS, Conboy IM, Conboy MJ, Shen J, Rando TA. A temporal switch from notch to Wnt signaling in muscle stem cells is necessary for normal adult myogenesis. Cell Stem Cell 2008; 2: 50-59.
27. Kuang S, Gillespie MA, Rudnicki MA. Niche regulation of muscle satellite cell selfrenewal and differentiation. Cell Stem Cell 2008; 2: 22-31.
28. von Maltzahn J, Chang NC, Bentzinger CF, Rudnicki MA. Wnt signaling in myogenesis. Trends Cell Biol 2012; 22: 602-609.
29. Raimondi L, Ciarapica R, De Salvo M, Verginelli F, Gueguen M, Martini C et al. Inhibition of Notch3 signalling induces rhabdomyosarcoma cell differentiation promoting p38 phosphorylation and p21(Cip1) expression and hampers tumour cell growth in vitro and in vivo. Cell Death Differ 2012; 19: 871-881.
30. Annavarapu SR, Cialfi S, Dominici C, Kokai GK, Uccini S, Ceccarelli S et al. Characterization of Wnt/beta-catenin signaling in rhabdomyosarcoma. Lab Invest 2013; 93: 1090-1099.
31. Chen EY, Deran MT, Ignatius MS, Grandinetti KB, Clagg R, McCarthy KM et al. Glycogen synthase kinase 3 inhibitors induce the canonical WNT/beta-catenin pathway to suppress growth and self-renewal in embryonal rhabdomyosarcoma. Proc Natl Acad Sci USA 2014; 111: 5349-5354.
32. Hirotsu M, Setoguchi T, Matsunoshita Y, Sasaki H, Nagao H, Gao H et al. Tumour formation by single fibroblast growth factor receptor 3-positive rhabdomyosarcoma-initiating cells. Br J Cancer 2009; 101: 2030-2037.
33. Gage PJ, Rhoades W, Prucka SK, Hjalt T. Fate maps of neural crest and mesoderm in the mammalian eye. Invest Ophthalmol Vis Sci 2005; 46: 4200-4208.
34. Buckingham M, Relaix F. The role of Pax genes in the development of tissues and organs: Pax3 and Pax7 regulate muscle progenitor cell functions. Annu Rev Cell Dev Biol 2007; 23: 645-673.
35. Liu P, Johnson RL. Lmx1b is required for murine trabecular meshwork formation and for maintenance of corneal transparency. Dev Dyn 2010; 239: 2161-2171.
36. Nitzki F, Zibat A, Frommhold A, Schneider A, Schulz-Schaeffer W, Braun T et al. Uncommitted precursor cells might contribute to increased incidence of embryonal rhabdomyosarcoma in heterozygous Patched1-mutant mice. Oncogene 2011; 30: 4428-4436.
37. Rajurkar M, Huang H, Cotton JL, Brooks JK, Sicklick J, McMahon AP et al. Distinct cellular origin and genetic requirement of Hedgehog-Gli in postnatal rhabdomyosarcoma genesis. Oncogene 2014; 33: 5370-5378.
38. Pressey JG, Haas MC, Pressey CS, Kelly VM, Parker JN, Gillespie GY et al. CD133 marks a myogenically primitive subpopulation in rhabdomyosarcoma cell lines that are relatively chemoresistant but sensitive to mutant HSV. Pediatr Blood Cancer 2013; 60: 45-52.
39. Stecca B, Mas C, Clement V, Zbinden M, Correa R, Piguet V et al. Melanomas require HEDGEHOG-GLI signaling regulated by interactions between GLI1 and the RAS-MEK/AKT pathways. Proc Natl Acad Sci USA 2007; 104: 5895-5900.
40. Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of cells in vitro. Nat Protoc 2006; 1: 2315-2319.